Japan’s Sawai Pharmaceutical Co Ltd is buying the generic drug business of U.S. drug maker Upsher-Smith Laboratories Inc for $1.05 billion, marking the Osaka-based generic drugmaker’s first overseas acquisition.
Sawai said on Thursday it is acquiring the business of the Minnesota-based company from the founding family to expand its presence in the United States, whose generic drug market it estimates at around 10 trillion yen ($91.87 billion), the world’s largest.
Sawai’s move to diversify geographically comes amid slow growth in Japan’s overall generic drugs market. And though the Japanese government aims to boost usage of generic drugs, growth may not be commensurate as prices of generic drugs are typically cheaper than patented ones.
Japan’s generic drug market currently is around a tenth of the U.S. market. It was worth 836.4 billion yen in 2016 and will grow to 1 trillion yen in 2020, according to research firm Fuji Keizai Co.
Sawai will use cash and bank loans for the acquisition.
The Japanese drugmaker plans to complete the deal by the end of June. The acquisition will not affect its earnings forecast for the year ended March, Sawai said.
By Chris Gallagher and Junko Fujita
Source: Reuters
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
